16302-35-5

Basic information

• Product Name: 3,6-dihydro-4-methyl-2H-pyran
• Synonyms: 3,6-dihydro-4-methyl-2H-pyran;3,6-dihydro-4-methyl-2H-pyrane;4-Methyl-3,6-dihydro-2H-pyran;Einecs 240-390-1;2H-Pyran, 3,6-dihydro-4-methyl-
• CAS NO: 16302-35-5
• Molecular Formula: C₆H₁₀O
• Molecular Weight: 98.143
• EINECS: 240-390-1
• Mol File: 16302-35-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 117.5°C (estimate)
• Flash Point: 14.3°C
• Appearance: /
• Density: 0.9120
• Vapor Pressure: 17.8mmHg at 25°C
• Refractive Index: 1.4495
• CAS DataBase Reference: 3,6-dihydro-4-methyl-2H-pyran(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dihydro-4-methyl-2H-pyran(16302-35-5)
• EPA Substance Registry System: 3,6-dihydro-4-methyl-2H-pyran(16302-35-5)

Safety Data

• Hazardous Substances Data: 16302-35-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H10O/c1-6-2-4-7-5-3-6/h2H,3-5H2,1H3

Upstream product

• 766-15-4 4,4-dimethyl-1,3-dioxane 
• 141-78-6 ethyl acetate 
• 79862-81-0 3,4-dibromo-4-methyltetrahydropyran 
• 105-53-3 diethyl malonate 
• 50-00-0 formaldehyd 
• 115-11-7 isobutene 
• 36838-71-8 4-methylene-tetrahydro-pyran 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 123-54-6 acetylacetone 
• 10150-87-5 1-acetoxybutan-3-one 
• 106-95-6 allyl bromide 
• 590-86-3 isovaleraldehyde 
• 110-62-3 pentanal 
• 78-84-2 isobutyraldehyde 

Downstream Products

• 7525-58-8 trans-3-hydroxymethyl-4-hydroxy-4-methyltetrahydropyran 
• 1195-96-6 trans-10-methyl-1,3,7-trioxadecalin 
• 1195-96-6 cis-10-methyl-1,3,7-trioxadecalin 
• 84186-03-8 3-hydroxymethyl-4-methyl-3,6-dihydropyran 
• 101529-25-3 2-(3,4-dihydro-2,6-dimethyl-2H-1-benzopyran)-2-ethanol 
• 79907-48-5 2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethanol 
• 101529-23-1 2,5,7,8-Tetramethyl-2-vinyl-chroman-6-ol 
• 78294-52-7 Tetrahydro-4-methyl-3-(4-methylphenylsulfonylamino)-4-pyranol 
• 89481-94-7 2-(3,4-dihydro-6-hydroxy-2-methyl-2H-1-benzopyran)-2-ethanol 
• 4717-96-8 4-methyltetrahydropyran 
• 994-49-0 hexaethyl disiloxane 
• 84186-00-5 4-methyl-4-trifluoroacetoxytetrahydropyran 
• 101529-26-4 2-(3,4-dihydro-7-hydroxy-2-methyl-2H-1-benzopyran)-2-ethanol 
• 36838-71-8 4-methylene-tetrahydro-pyran 

Relevant articles and documents

Dimerization of sodium enolates of malonic ester and acetylacetone effected by the action of 4-methyl-3,4-dibromotetrahydropyran

-

Isoprene synthesis from formaldehyde and isobutene over Keggin-type heteropolyacids supported on silica

Gas phase Prins condensation of isobutene with formaldehyde has been studied over different Keggin-type heteropolyacids supported on amorphous silica. The catalysts were characterized by elemental analysis, X-ray diffraction, low temperature nitrogen adsorption, TPD of ammonia, FTIR of adsorbed pyridine and NMR spectroscopy. The activity of the supported heteropoly compounds was found to increase in the following order: H4SiMo12O40 3PMo12O40 4SiW12O40 ≈ H3PW12O40. The lower activity of the supported molybdenum heteropolyacids was attributed to their low thermal stability and partial decomposition during catalyst activation, which resulted in lower acidity. The variation of HPA content from 5 to 33 wt% was also shown to increase catalyst activity. Based on the relationship between the content of weak Br?nsted sites, the amount and type of carbonaceous deposits and the catalytic activity, it was concluded that the generation of working active sites over HPA catalysts involves the formation of unsaturated branched surface species over weak Br?nsted sites. These active carbonaceous species are responsible for selective isoprene synthesis. The best catalyst performance is observed over the catalyst with 20 wt% of H3PW12O40, which shows an isoprene yield of 48% with a selectivity of 63%.

PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyrazolo [4,3-c] cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.